evaluating the lipi for first line immunotherapy in nsclc
Published 3 years ago • 85 plays • Length 5:02Download video MP4
Download video MP3
Similar videos
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
2:14
first-line treatment decision making for elderly patients with nsclc
-
2:22
moving immunotherapy to earlier lines in nsclc
-
1:44
pd-l1 testing in first-line treatment of nsclc
-
3:08
choosing immunotherapy as front line therapy for non-actionable nsclc
-
4:34
immunotherapy for first line therapy of advanced nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
1:09:47
how to select the right immunotherapy for first-line treatment of advanced nsclc
-
1:06
improving outcomes for patients with metastatic nsclc with immunotherapy
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
2:08
using first-line immunotherapy in stage 4 nsclc
-
1:10:25
how to select the right immunotherapy for first-line treatment of advanced nsclc
-
2:14
is there a role for pd l1 testing after first line treatment for advanced non small cell lung cancer
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
2:59
chemotherapy in combination with immunotherapy for the treatment of metastatic thymic carcinoma
-
6:55
the prognostic value of ctdna in nsclc treated with neoadjuvant chemoimmunotherapy
-
1:49
adcs for lung cancer
-
1:48
assessing immunotherapy in various subtypes of lung cancer